Novartis Phase III data shows atrasentan reduces proteinuria in IgA nephropathy patients

From GlobeNewswire: 2024-05-25 06:15:00

Novartis’ ALIGN study showed that atrasentan, along with supportive care, led to a 36.1% reduction in proteinuria compared to placebo + supportive care in IgA nephropathy patients. Atrasentan is an ETA receptor antagonist that can potentially reduce persistent proteinuria and preserve kidney function. Up to 30% of IgAN patients with persistent proteinuria proceed to kidney failure within 10 years, highlighting the need for effective treatments. Novartis aims to explore various treatment options to slow down IgAN progression with different modes of action. The Phase III study results demonstrate the potential of atrasentan in treating this rare kidney disease.



Read more at GlobeNewswire: Novartis atrasentan Phase III data show clinically